Direct Antithrombins
- 1 January 2007
- journal article
- Published by Springer Science and Business Media LLC in American Journal of Cardiovascular Drugs
- Vol. 7 (4), 249-257
- https://doi.org/10.2165/00129784-200707040-00003
Abstract
Direct thrombin inhibitors have several potential advantages over indirect thrombin inhibitors such as heparin. Bivalirudin, a bivalent direct thrombin inhibitor, is most commonly used in clinical practice and has a proven role in contemporary interventional medicine with elective percutaneous coronary intervention (PCI) as well as in patients with non-ST-elevation acute coronary syndrome (NSTEACS). Results from well-controlled clinical trials have shown that bivalirudin is associated with an approximate 50% reduction in major bleeding while having similar effects on incidence of death and myocardial infarction (MI) compared with herapin or enoxaparin and glycoprotein IIb/IIIa inhibitors. Bivalirudin has been successfully used in off- and on-pump cardiac surgery.Keywords
This publication has 39 references indexed in Scilit:
- Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formationBlood Coagulation & Fibrinolysis, 2007
- Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary SyndromesCirculation, 2006
- Argatroban, Bivalirudin, and Lepirudin do not Decrease Clot Propagation and Strength as Effectively as Heparin-activated Antithrombin In VitroThe Journal of Heart and Lung Transplantation, 2006
- A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: The EVOLUTION-ON studyThe Journal of Thoracic and Cardiovascular Surgery, 2006
- Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial)The American Journal of Cardiology, 2005
- Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary interventionThe American Journal of Cardiology, 2004
- Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)The American Journal of Cardiology, 2004
- Non-invasive detection of early infarct vessel patency by resolution of ST-segment elevation in patients with thrombolysis for acute myocardial infarction. Results of the angiographic substudy of the Hirudin for Improvement of Thrombolysis (HIT)-4 trialEuropean Heart Journal, 2001
- Interactions of Hirudin-Based Inhibitor with Thrombin: Critical Role of the IleH59 Side Chain of the InhibitorBiochemistry, 1995
- Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.JCI Insight, 1990